Oncobiomix
San Antonio, US · Founded 2023 · Delaware corporation
Oncobiomix develops AI-powered microbiome diagnostics and therapeutics, using gut microbiome analysis as a "biosensor" for cancer detection and gut health. The company offers microbiome testing (RebiomiX) in which samples undergo microbial DNA extraction and AI-based analysis to generate health reports.
Founders & leadership
ML
Michael LissCEO
JW
James WhiteCTO
CL
Charles LeachCMO
Reported raises · per SEC filings
Form D private placements$500K disclosed across 1 round · 2023
▶$500KraisedSep 2025 · 12 investors · BiotechnologyRule 506(b)
▶$500KraisedSep 2025 · 12 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Michael Andre LissExecutive Officer, Director
- Offering amount
- $1M
- Amount sold
- $500K
- First sale
- Oct 2023
- Incorporated
- Corporation, Delaware, 2023
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Frequently asked questions
- What does Oncobiomix do?
- Oncobiomix develops AI-powered microbiome diagnostics and therapeutics, using gut microbiome analysis as a "biosensor" for cancer detection and gut health. The company offers microbiome testing (RebiomiX) in which samples undergo microbial DNA extraction and AI-based analysis to generate health reports.
- How much funding has Oncobiomix raised?
- Oncobiomix has disclosed $500K raised across 1 round.
- Where is Oncobiomix headquartered?
- Oncobiomix is headquartered in San Antonio, US.